Skip to main content Skip to search Skip to main navigation

Swissmedic: Update of Responsible Person Requirements

Swissmedic published an updated version of Technical Interpretation 17: Responsible Person: requirements on 26 August 2024. The document outlines the Swiss Inspectorate’s understanding of an RP in accordance with the Medicinal Products Licensing Ordinance (MPLO). It can also serve as a reference for companies to assess whether an individual meets the criteria for applying to Swissmedic to act as an RP.

What’s new in Version 7.0?

  • Chapters 5.1 and 5.2 provide precise information about educational aspects and activities where experience in GDP/GMP practices is required.
  • The experience with regulatory issues as acceptable criterium has been removed and a precision about the experience required for an area with specific risks was added (e.g. sterile medicinal products)
  • It is specified that brokerage, agents, and trade in foreign countries do not count as GDP experience.
  • Language requirements are clarified in Chapter 5.5
  • Chapter 5.6. specifies the understanding of what is the direct supervision of a facility.
  • New Chapter 5.6.1 on remote technical and market release
  • Chapter 5.2 includes:
  • - Precisions about the expected presence on site of the RPs,
    - Precision of conditions permitting a reduction of physical presence on site,
    - Precision on the cases where an intensified presence on site is expected.
  • New Chapter on 5.6.3 about the workload of RPs
  • Chapter 6 clarifies that the same requirements apply to the deputy RP, inclusive domicile.
  • Chapter 7 specifies possibilities and conditions for task delegation as well as critical processes and release activities.
  • Chapter 8 includes the event of absence of the RP beyond the normal holiday leave.

In most cases, compliance with the previous technical interpretation guarantees compliance with the current version. The license holder is generally required to adapt immediately. Also, for the inspectorates the updated technical interpretation applies with immediate effect.

License holders with approved responsible persons who do not meet the requirements have 12 months to make the necessary adjustments. This could be either by appointing a new RP with the required language skills or by ensuring that an RP acquires the required language skills within this period. Swissmedic expects responsible persons to speak one of the official local languages of the canton where the inspection takes place and where the site is located.


Source:

Swissmedic: Technical interpretation 17 “Responsible Person: requirements”

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next